A Phase 1 Study of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

被引：5

作者：

Smith, Stephen D. ^{[1
]}

Starodub, Alexander ^{[2
]}

Stevens, Don A. ^{[3
]}

Shastri, Aditi ^{[4
]}

Porcu, Pierluigi ^{[5
]}

Feldman, Tatyana ^{[6
]}

Ewesuedo, Reggie ^{[7
]}

DeSavi, Chris ^{[7
]}

Dey, Joyoti ^{[7
]}

Agarwal, Sagar ^{[7
]}

Donohue, Sean ^{[7
]}

Perea, Rachelle ^{[7
]}

Klaus, Christine ^{[7
]}

Gollob, Jared ^{[7
]}

机构：

[1] Univ Washington, Fred Hutchinson Canc Ctr, Div Med Oncol, Seattle, WA 98195 USA

[2] Christ Hosp, Cincinnati, OH 45219 USA

[3] Norton Canc Inst, Norton Healthcare, Louisville, KY USA

[4] Albert Einstein Coll Med, Montefiore Med Ctr, Oncol, Hematol Oncol, Bronx, NY 10467 USA

[5] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr Jefferson Hlth, Philadelphia, PA 19107 USA

[6] Hackensack Univ, HackensackMeridianHlth Sch Med, John Theurer Canc Ctr, Med Ctr, Hackensack, NJ USA

[7] Kymera Therapeut, Watertown, MA USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-169514

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：12024 / 12025

页数：2

共 50 条

[1] Phase 1 study of KT-333, a targeted protein degrader, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia, and solid tumors
Starodub, Alexander
Gollerkeri, Ashwin
De Savi, Chris
Dey, Joyoti
Agarwal, Sagar
Donohue, Sean
Perea, Rachelle
Klaus, Christine
Gollob, Jared
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[2] Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors
Shastri, Aditi
Feldman, Eric J.
Starodub, Alexander N.
Feldman, Tatyana
Rodriguez, Cristina P.
Epstein-Peterson, Zachary D.
Stevens, Don A.
Olszewski, Adam J.
Huen, Auris O.
Porcu, Pierluigi
Reneau, John C.
Barta, Stefan K.
Marchi, Enrica
Mattour, Ahmad H.
Pinter-Brown, Lauren C.
Perea, Rachelle
Donohue, Sean
Dey, Joyoti
Agarwal, Sagar
Karnik, Rahul
Gollerkeri, Ashwin
Gollob, Jared
Smith, Stephen D.
BLOOD, 2023, 142
[3] Multiple STAT3 Mutations In Different Lymphocyte Clones Of Large Granular Lymphocytic Leukemia Patients
Rajala, Hanna L. M.
Olson, Thomas
Lagstroem, Sonja
Ellonen, Pekka
Zaman, Syed Arshi Uz
Andersson, Emma I.
Clemente, Michael J.
Jerez, Andres
Porkka, Kimmo
Maciejewski, Jaroslaw P.
Loughran, Thomas P., Jr.
Mustjoki, Satu
BLOOD, 2013, 122 (21)
[4] Phase 1 study of KT-413, a targeted protein degrader, in adult patients with relapsed or refractory B-cell non-Hodgkin lymphoma
Stevens, Don A.
Ewesuedo, Reginald
McDonald, Alice
Agarwal, Sagar
Henrick, Patrick
Perea, Rachelle
Gollerkeri, Ashwin
Gollob, Jared
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[5] Systematic STAT3 sequencing in patients with unexplained cytopenias identifies unsuspected large granular lymphocytic leukemia
Morgan, Elizabeth A.
Lee, Mark N.
DeAngelo, Daniel J.
Steensma, David P.
Stone, Richard M.
Kuo, Frank C.
Aster, Jon C.
Gibson, Christopher J.
Lindsley, R. Coleman
BLOOD ADVANCES, 2017, 1 (21) : 1786 - 1789
[6] STAT3 mutations are frequent in CD30+T-cell lymphomas and T-cell large granular lymphocytic leukemia
Ohgami, R. S.
Ma, L.
Merker, J. D.
Martinez, B.
Zehnder, J. L.
Arber, D. A.
LEUKEMIA, 2013, 27 (11) : 2244 - 2247
[7] Systematic STAT3 Mutation Testing Identifies Patients with Unsuspected T-Cell Large Granular Lymphocytic Leukemia
Morgan, Elizabeth A.
Lee, Mark N.
DeAngelo, Daniel J.
Steensma, David P.
Stone, Richard M.
Kuo, Frank C.
Aster, Jon C.
Gibson, Christopher J.
Lindsley, R. Coleman
BLOOD, 2016, 128 (22)
[8] STAT3 mutations are frequent in CD30+ T-cell lymphomas and T-cell large granular lymphocytic leukemia
R S Ohgami
L Ma
J D Merker
B Martinez
J L Zehnder
D A Arber
Leukemia, 2013, 27 : 2244 - 2247
[9] Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors
Meany, Holly J.
Widemann, Brigitte C.
Hinds, Pamela S.
Bagatell, Rochelle
Shusterman, Suzanne
Stern, Emily
Jayaprakash, Nalini
Peer, Cody J.
Figg, William D.
Hall, O. Morgan
Sissung, Tristan M.
Kim, Aerang
Fox, Elizabeth
London, Wendy B.
Rodriguez-Galindo, Carlos
Minturn, Jane E.
Dome, Jeffrey S.
PEDIATRIC BLOOD & CANCER, 2021, 68 (11)
[10] A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Barr, Paul M.
Hill, Brian T.
Ma, Shuo
Baran, Andrea M.
Bui, Andrew
Meacham, Philip J.
Morrison, Ashley
Liesveld, Jane L.
Mulford, Deborah A.
Sportelli, Peter
Miskin, Hari P.
Weiss, Michael S.
Friedberg, Jonathan W.
Zent, Clive S.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (03) : 9 - 10

← 1 2 3 4 5 →